167 related articles for article (PubMed ID: 36230945)
21. Anti-L1CAM radioimmunotherapy is more effective with the radiolanthanide terbium-161 compared to lutetium-177 in an ovarian cancer model.
Grünberg J; Lindenblatt D; Dorrer H; Cohrs S; Zhernosekov K; Köster U; Türler A; Fischer E; Schibli R
Eur J Nucl Med Mol Imaging; 2014 Oct; 41(10):1907-15. PubMed ID: 24859811
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of novel anti-CEACAM6 antibody-based conjugates for radioimmunotheranostics of pancreatic ductal adenocarcinoma.
Kong Y; Xie F; Zhang Z; Wang S; Zhang Y; Di Y; Zhou Z; Jiang D; Li J; Huang Q; Wang J; Li X; Pan Z; Ni R; Guan Y
Eur Radiol; 2023 Oct; 33(10):7077-7088. PubMed ID: 37166496
[TBL] [Abstract][Full Text] [Related]
23. Combination of lutetium-177 labelled anti-L1CAM antibody chCE7 with the clinically relevant protein kinase inhibitor MK1775: a novel combination against human ovarian carcinoma.
Lindenblatt D; Terraneo N; Pellegrini G; Cohrs S; Spycher PR; Vukovic D; Béhé M; Schibli R; Grünberg J
BMC Cancer; 2018 Sep; 18(1):922. PubMed ID: 30253737
[TBL] [Abstract][Full Text] [Related]
24. Dual-Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates.
Razumienko EJ; Chen JC; Cai Z; Chan C; Reilly RM
J Nucl Med; 2016 Mar; 57(3):444-52. PubMed ID: 26429962
[TBL] [Abstract][Full Text] [Related]
25. In vivo and in vitro inhibition of pancreatic cancer growth by targeted alpha therapy using 213Bi-CHX.A"-C595.
Qu CF; Songl YJ; Rizvi SM; Li Y; Smith R; Perkins AC; Morgenstern A; Brechbiel M; Allen BJ
Cancer Biol Ther; 2005 Aug; 4(8):848-53. PubMed ID: 16082185
[TBL] [Abstract][Full Text] [Related]
26. Tissue and serum MUC1 mucin detection in breast cancer patients.
Croce MV; Isla-Larrain MT; Demichelis SO; Gori JR; Price MR; Segal-Eiras A
Breast Cancer Res Treat; 2003 Oct; 81(3):195-207. PubMed ID: 14620915
[TBL] [Abstract][Full Text] [Related]
27. Preclinical Evaluation of
Prignon A; Provost C; Alshoukr F; Wendum D; Couvelard A; Barbet J; Forgez P; Talbot JN; Gruaz-Guyon A
Mol Pharm; 2019 Jun; 16(6):2776-2784. PubMed ID: 31013092
[TBL] [Abstract][Full Text] [Related]
28. Radioimmunotherapy of a human lung cancer xenograft with monoclonal antibody RS7: evaluation of (177)Lu and comparison of its efficacy with that of (90)Y and residualizing (131)I.
Stein R; Govindan SV; Chen S; Reed L; Richel H; Griffiths GL; Hansen HJ; Goldenberg DM
J Nucl Med; 2001 Jun; 42(6):967-74. PubMed ID: 11390564
[TBL] [Abstract][Full Text] [Related]
29. Effect of glycosylation of a synthetic MUC1 mucin-core-related peptide on recognition by anti-mucin antibodies.
Spencer DI; Price MR; Tendler SJ; De Matteis CI; Stadie T; Hanisch FG
Cancer Lett; 1996 Feb; 100(1-2):11-5. PubMed ID: 8620429
[TBL] [Abstract][Full Text] [Related]
30. Impact of DOTA-Chelators on the Antitumor Activity of
Wojdowska W; Karczmarczyk U; Balog L; Sawicka A; Pöstényi Z; Kovács-Haász V; Polyák A; Laszuk E; Mikołajczak R; Garnuszek P
Cancer Biother Radiopharm; 2020 Oct; 35(8):558-562. PubMed ID: 32255676
[No Abstract] [Full Text] [Related]
31. Anti-tumor activity of antibody drug conjugate targeting aspartate-β-hydroxylase in pancreatic ductal adenocarcinoma.
Nagaoka K; Bai X; Ogawa K; Dong X; Zhang S; Zhou Y; Carlson RI; Jiang ZG; Fuller S; Lebowitz MS; Ghanbari H; Wands JR
Cancer Lett; 2019 May; 449():87-98. PubMed ID: 30768955
[TBL] [Abstract][Full Text] [Related]
32. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re.
Brouwers AH; van Eerd JE; Frielink C; Oosterwijk E; Oyen WJ; Corstens FH; Boerman OC
J Nucl Med; 2004 Feb; 45(2):327-37. PubMed ID: 14960657
[TBL] [Abstract][Full Text] [Related]
33. Mucin 1 Regulates Cox-2 Gene in Pancreatic Cancer.
Nath S; Roy LD; Grover P; Rao S; Mukherjee P
Pancreas; 2015 Aug; 44(6):909-17. PubMed ID: 26035123
[TBL] [Abstract][Full Text] [Related]
34. Patterns of MUC1 tissue expression defined by an anti-MUC1 cytoplasmic tail monoclonal antibody in breast cancer.
Croce MV; Isla-Larrain MT; Rua CE; Rabassa ME; Gendler SJ; Segal-Eiras A
J Histochem Cytochem; 2003 Jun; 51(6):781-8. PubMed ID: 12754289
[TBL] [Abstract][Full Text] [Related]
35. Evidence of
Marenco M; Lodola L; Persico MG; Frangipane V; Facoetti A; Aprile C; Hodolič M
Curr Pharm Biotechnol; 2018; 19(9):754-759. PubMed ID: 30160211
[TBL] [Abstract][Full Text] [Related]
36. Preparation of
Pandey U; Kameswaran M; Gamre N; Dash A
J Labelled Comp Radiopharm; 2019 Apr; 62(4):158-165. PubMed ID: 30663095
[TBL] [Abstract][Full Text] [Related]
37. Electrochemiluminescence biosensor for specific detection of pancreatic ductal carcinoma through dual targeting of MUC1 and miRNA-196a.
Chen Y; Ye Z; Ma M; Yang J; Liu R; Zhang Y; Ma P; Song D
Biosens Bioelectron; 2024 Jun; 254():116241. PubMed ID: 38527406
[TBL] [Abstract][Full Text] [Related]
38. Aberrant methylation of MUC1 and MUC4 promoters are potential prognostic biomarkers for pancreatic ductal adenocarcinomas.
Yokoyama S; Higashi M; Kitamoto S; Oeldorf M; Knippschild U; Kornmann M; Maemura K; Kurahara H; Wiest E; Hamada T; Kitazono I; Goto Y; Tasaki T; Hiraki T; Hatanaka K; Mataki Y; Taguchi H; Hashimoto S; Batra SK; Tanimoto A; Yonezawa S; Hollingsworth MA
Oncotarget; 2016 Jul; 7(27):42553-42565. PubMed ID: 27283771
[TBL] [Abstract][Full Text] [Related]
39. An antibody-drug conjugate targeting a GSTA glycosite-signature epitope of MUC1 expressed by non-small cell lung cancer.
Pan D; Tang Y; Tong J; Xie C; Chen J; Feng C; Hwu P; Huang W; Zhou D
Cancer Med; 2020 Dec; 9(24):9529-9540. PubMed ID: 33084221
[TBL] [Abstract][Full Text] [Related]
40. DTPA(DOTA)-Nimotuzumab Radiolabeling with Generator-produced Thorium for Radioimmunotherapy of EGFR-overexpressing Carcinomas.
Bravo MG; Egorova BV; Vasiliev AN; Lapshina EV; Ermolaev SV; Durymanov MO
Curr Radiopharm; 2023 Jun; 16(3):233-242. PubMed ID: 36809934
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
